Recently Viewed
Clear All$290.10
$-12.59
(-4.16%)
As on 27-Mar-2026 16:28EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$8,308 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
9.5
Industry P/E
--
EV/EBITDA
-6.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$39
EPS
$-13.5
Face value
--
Shares outstanding
27,850,833
CFO
$-527.50 Mln
EBITDA
$-631.41 Mln
Net Profit
$-627.10 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Praxis Precision Medicines Inc (PRAX)
| -1.6 | -14.8 | 7.9 | 659.6 | 187.1 | -8.9 | -- |
|
BSE Sensex
| -13.1 | -10.5 | -13.5 | -4.8 | 8.6 | 8.5 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Praxis Precision Medicines Inc (PRAX)
| 283.0 | 241.9 | -37.6 | -87.9 | -64.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Praxis Precision Medicines Inc (PRAX)
|
290.1 | 8,308.2 | 0.0 | -303.3 | -- | -45.8 | -- | 9.5 |
| 57.8 | 7,888.0 | 1,091.0 | 202.3 | 31.6 | 31.3 | 35.2 | 13.9 | |
| 62.5 | 7,599.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 41.5 | 11,065.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.8 | 5.0 | |
| 84.6 | 11,173.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 61.6 | 7,485.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.7 | 153.4 | |
| 7.4 | 8,708.1 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 510.7 | 10,120.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 451.2 | 12,842.8 | 2,530.2 | 451.1 | 21.3 | 70.2 | 29.6 | 28.5 | |
| 96.7 | 7,450.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The... company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Read more
President, CEO & Director
Mr. Marcio Silva De'Souza M.B.A.
President, CEO & Director
Mr. Marcio Silva De'Souza M.B.A.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Praxis Precision Medicines Inc (PRAX) is $290.10 (NASDAQ) as of 27-Mar-2026 16:28 EDT. Praxis Precision Medicines Inc (PRAX) has given a return of 187.13% in the last 3 years.
Since, TTM earnings of Praxis Precision Medicines Inc (PRAX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-21.87
|
7.55
|
|
2024
|
-8.41
|
3.45
|
|
2023
|
-1.64
|
2.90
|
|
2022
|
-0.04
|
0.10
|
|
2021
|
-0.35
|
0.24
|
The 52-week high and low of Praxis Precision Medicines Inc (PRAX) are Rs 356.00 and Rs 26.70 as of 28-Mar-2026.
Praxis Precision Medicines Inc (PRAX) has a market capitalisation of $ 8,308 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Praxis Precision Medicines Inc (PRAX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.